Mostow S R, Mayfield J L, Marr J J, Drucker J L
Department of Medicine, University of Colorado School of Medicine, Denver.
Am J Med. 1988 Aug 29;85(2A):30-3.
Patients with frequent recurrences of genital herpes were treated with oral acyclovir tablets, 800 mg, or placebo once daily for two years. Confirmed recurrences for all patients were treated with acyclovir capsules, 200 mg orally five times per day, for five days. Of 46 patients enrolled, 18 of 22 acyclovir recipients and 14 of 24 placebo recipients completed two years of study. Patients receiving acyclovir experienced a mean of 0.184 recurrences/month compared with a mean of 0.977 recurrences/month for patients receiving placebo (p less than 0.0001). A total of 28 percent of acyclovir recipients and no placebo recipients remained free of recurrences for two years. The low rate of recurrences in the acyclovir group remained consistent throughout the study. No serious clinical or laboratory abnormalities associated with acyclovir were observed. The 800-mg acyclovir tablet given daily was well-tolerated and effective for two years in the management of recurrent genital herpes.
复发性生殖器疱疹患者接受口服阿昔洛韦片治疗,剂量为800毫克,或服用安慰剂,每日一次,为期两年。所有患者确诊复发时,均口服200毫克阿昔洛韦胶囊,每日5次,持续5天。在纳入研究的46例患者中,22例接受阿昔洛韦治疗的患者中有18例、24例接受安慰剂治疗的患者中有14例完成了两年的研究。接受阿昔洛韦治疗的患者平均每月复发0.184次,而接受安慰剂治疗的患者平均每月复发0.977次(p<0.0001)。共有28%接受阿昔洛韦治疗的患者两年内未复发,而接受安慰剂治疗的患者无一例未复发。在整个研究过程中,阿昔洛韦组的低复发率保持一致。未观察到与阿昔洛韦相关的严重临床或实验室异常。每日服用800毫克阿昔洛韦片耐受性良好,对复发性生殖器疱疹的治疗有效,为期两年。